Economic evaluation of Korea’s COVID-19 response projects in Uzbekistan.

Publication date: Jul 10, 2025

This study aims to assess the economic feasibility and broader policy implications of the Korea International Cooperation Agency’s (KOICA) official development assistance (ODA) projects for the COVID-19 emergency response in Uzbekistan through a cost-benefit analysis. The primary research question is to evaluate whether the interventions provide sufficient economic returns relative to their costs while informing future pandemic preparedness of response strategies. A cost-benefit analysis using quantitative methods was performed to assess the financial impact of the COVID-19 ODA projects. The study was conducted in Uzbekistan, focusing on KOICA’s COVID-19 emergency response projects from January 2020 to December 2021. The intervention involved the implementation of KOICA’s COVID-19 emergency response activities, including early diagnosis support, establishment of rapid response bases, provision of medical equipment and emergency relief efforts in Uzbekistan. The primary outcome measure is the net present value (NPV) and benefit/cost ratio of the project. Secondary outcome measures are the project’s effectiveness in terms of death prevention, reduction in medical costs and timely COVID-19 testing. The analysis revealed a total programme cost of US$11 353 173, with a net benefit ranging from US$21 026 032 to US$34 573 403, and a benefit/cost ratio between 1. 85 and 3. 05. A detailed examination of costs and benefits highlighted the programme’s positive NPV and benefit/cost ratio, indicating its economic feasibility. The study also underscored the programme’s effectiveness in preventing deaths, reducing medical costs and providing timely COVID-19 testing. The findings confirm that KOICA’s COVID-19 emergency response projects in Uzbekistan were economically viable and effective. The study highlights the importance of integrating economic evaluations into ODA assessments, particularly for emergency response and infectious disease control. It recommends expanding the use of quantitative analysis to optimise resource allocation and improve decision-making in future global health crises.

Open Access PDF

Concepts Keywords
December Cost-Benefit Analysis
Financial COVID-19
Pandemic COVID-19
Uzbekistan HEALTH ECONOMICS
Health economics
Humans
International Cooperation
Pandemics
Republic of Korea
SARS-CoV-2
Uzbekistan

Semantics

Type Source Name
disease MESH COVID-19
disease MESH emergency
disease IDO intervention
disease MESH death
disease MESH infectious disease
pathway REACTOME Infectious disease
drug DRUGBANK Coenzyme M
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Spinosad
drug DRUGBANK Trestolone
drug DRUGBANK Abacavir
disease IDO country
disease MESH infections
disease IDO facility
drug DRUGBANK Oxygen
disease IDO quality
disease MESH complications
disease IDO infection
drug DRUGBANK Stavudine
disease MESH premature mortality
disease IDO production
disease IDO symptom
disease IDO infected population
disease IDO contact tracing
disease IDO process
disease MESH education level
drug DRUGBANK Ilex paraguariensis leaf
disease MESH uncertainty
disease MESH unemployment
pathway REACTOME Translation
disease IDO infectivity

Original Article

(Visited 5 times, 1 visits today)